Paolo Ascierto, Director of Department Melanoma at Cancer Immunotherapy and Development Therapeutics, shared a post on LinkedIn:
“Strategic Innovation in Oncology: Immunotherapy Before Surgery
Recent research highlights a major shift in approach — delivering immunotherapy before surgery is showing promising results across several malignancies, including melanoma; lung, colorectal, and triple-negative breast cancer.
This neoadjuvant strategy is associated with fewer relapses, stronger treatment responses, and renewed hope for many patients. A clinical innovation translating into measurable patient benefit.”
More posts featuring Paolo Ascierto.